(Q34352747)

1 August 2017

What's new in atopic dermatitis? (English)

1 reference

1 August 2017

Eedy DJ

1

1 reference

PubMed ID

11531827

1 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

British Journal of Dermatology

1 August 2017

1 reference

1 August 2017

145

1 reference

1 August 2017

3

1 reference

1 August 2017

380-384

1 reference

Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee

1 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The prevalence of childhood atopic eczema in a general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Counci

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The prevalence of atopic dermatitis in Oregon schoolchildren

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Age of entry to day nursery and allergy in later childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Childhood eczema: disease of the advantaged?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The excess of atopic eczema in East Germany is related to the intrinsic type

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Is there a geographical variation in eczema prevalence in the UK? Evidence from the 1958 British Birth Cohort Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The role of allergens in allergic airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

A major susceptibility locus for atopic dermatitis maps to chromosome 3q21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Functional diversity of helper T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Evaluation of mite allergen-induced Th1 and Th2 cytokine secretion of peripheral blood mononuclear cells from atopic dermatitis patients: association between IL-13 and mite-specific IgE levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The Infants' Dermatitis Quality of Life Index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Topical corticosteroid phobia in patients with atopic eczema

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

First experience of topical SDZ ASM 981 in children with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Ascomycin: an advance in the management of atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

A trial of oolong tea in the management of recalcitrant atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

What is the cost of atopic dermatitis in preschool children?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 1: audit of service structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

Superantigens and their potential role in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2133.2001.04373.X

10.1046/J.1365-2133.2001.04373.X

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11531827